FtsZ and RnpA as Valid Targets while Developing Novel Antimicrobials
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 23398
Special Issue Editor
Interests: drug discovery; medicinal chemistry, structure activity relationship; development of novel antimicrobials; FtsZ inhibitors; RnpA inhibitors; inhibition of bacterial cellular division process
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antimicrobial resistance is a serious and actual problem for public health. Investigating innovative antibacterial targets could be a favorable way to counteract this issue.
In order to approach this topic, in the last decade two important proteins have started being considered and exploited, due to their crucial role in bacterial viability and to their established druggability: FtsZ and RnpA.
Both FtsZ and RnpA are widely conserved among the highest priority pathogens and have limited to null homology with eukaryotic proteins, hoping for broad-spectrum antimicrobials with low cytotoxicity on human cells.
Starting from these considerations, this Special Issue would invite all researchers involved in fighting antimicrobial resistance by studying FtsZ and RnpA with different perspectives and positions. All manuscripts dealing with the design, synthesis, and the biological evaluation of novel antimicrobials targeting FtsZ and RnpA are welcome, as well as papers developing computational models, innovative assays, target-ligand characterization, crystallographic structures and biological mechanisms related to these two proteins.
I hope for extensive contributions from all over the world, in order to strongly sensitize on this urgent healthcare concern.
Dr. Valentina Straniero
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- FtsZ inhibitors
- RnpA inhibition
- bacteriostatic effect
- bactericidal effect
- bacterial cell division process
- mRNA turnover
- bacterial virulence factors
- antimicrobials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.